Efficacy and safety of certolizumab pegol after incomplete response to dmards in rheumatoid arthritis patients with low moderate disease activity: results from certain, a phase IIIB study

Aún no traducido Aún no traducido
Categoría Estudio primario
ConferenciaBritish Society for Rheumatology and British Health Professionals in Rheumatology Annual Meeting 2012; Glasgow, U.K. Published in: Rheumatology
Año 2012
Este artículo no tiene resumen
Epistemonikos ID: 39777ee6a3012babddb742bed24cb82da49fa5ff
First added on: Nov 01, 2017